Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026

Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates

Allschwil, Switzerland, October 20, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that new data on the phase 3 antifungal fosmanogepix, the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) will be presented at IDWeek 2026, which takes place from October 21 to 24 in Washington D.C., USA.

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “The breadth of data being presented at IDWeek across Basilea’s anti-infectives portfolio by us, our partners, collaborators and independent research groups, underscores the strong scientific interest in advancing the treatment of serious fungal and bacterial infections. These presentations continue to strengthen the evidence supporting our programs and their potential to address important unmet medical needs, including for pediatric patients.”

Fosmanogepix data presented at IDWeek 2026

Presentation: Fosmanogepix Expanded Access Experience in Pediatric Patients ≤11 Years of Age with Invasive Mold Infections
Presenting author: L. E. Hastings
Co-authors: K. L. Barros, M. L. Kussin, M. A. Kutny, J. B. Wood, Y. Vipulanandan, R. Banerjee, D. Dulek, T. S. Sharma, E. Kang, S. Maxwell, A. M. Green, D. Tyungu, M. M. Oldham, J. G. Lake, G. R. Alvira-Arill, E. Kitt, P. Gavin, N. DV De León, Y. Mozo del Castillo, E. Iosifidis, E. Roilides, D. S. Kohlfürst, J. Prattes, M. Hoenigl, O. O’Connor, J. Ryan, A. Howard-Jones, N. Maissen, V. A. Cruz Flores, H. Schlamm, K. Litherland, D. Ionescu, M. Engelhardt, E. Steletou, L. M. Kirkpatrick, J. C. Christenson, P. G. Pappas
Date & time: Friday, October 23, 2026, 10:42-10:54 am
Location: 201

Presentation: Activity of manogepix against Candida auris isolates from the United States
Presenting author: M. Winkler
Co-authors: A. Klauer, S. Edeker, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira
Date & time: Friday, October 23, 2026, 4:15-4:30 pm
Location: 103 AB

Poster #P-17: Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-18: Activity of manogepix against mold isolates across geographic regions
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-19: Activity of manogepix against yeast and mold isolates from 2025 in the United States
Presenting author: M. Winkler
Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Isavuconazole data presented at IDWeek 2026

Rapid-Fire Poster Session: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients [see also Poster #P-2022]
Rapid Fire presenters: M. A. Colaluca, K. Marsh, Y. Li, C. Otto, M. Ringer
Date & time: Friday, October 23, 2026, 12:30-12:35 pm
Location: RF Arena 1

Poster #P-31: Hepatotoxicity Signals Across Azole Antifungals: Is Isavuconazole Safer? A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
Presenting author: V. Thiruvadi
Co-authors: R. Ravichandran, Y. Kagzi, S. Ahsan, M. Alqaisieh, M. Kandula, D. Francisco
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Virtual Presentation

Poster #P-1645: Adoption of Isavuconazole in Pediatrics: A Multi-Center Survey
Presenting author: C. Lan
Co-authors: H. A. Jamal, M. Johnson, S. Vora
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-1922: Evaluation of Inpatient Isavuconazole Prescribing Practices at a Community-Based Cancer Center
Presenting author: W. Monier Texidor
Co-authors: S. Kim, J. Unzaga, A. Ramos Morales, L. Kemp, L. Amaya
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-2005: Invasive aspergillosis in kidney transplant recipients: A 20-year cohort from Colombia
Presenting author: I. Ramirez
Co-author: C. Ruiz
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Virtual presentation

Poster #P-2018: Epidemiology of Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplant Recipients at a Brazilian Cancer Center (2012–2022): Preliminary Data
Presenting author: M. V. Batista
Co-authors: A. Volpe, E. Veras; T. Monteiro-Silva, A. Luiza Marinho, B. Cal, A. Cordeiro, V. Bovolenta, M. Nascimento, J. Schmidt-Filho
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-2022: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients
Presenting author: M. A. Colaluca
Co-authors: K. Marsh, Y. Li, C. Otto, M. Ringer
Date & time: Friday, October 23, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-1372: Nationwide Retrospective Analysis of Isavuconazole Treatment for Histoplasmosis
Presenting author: C. A. Gentry
Co-authors: J. J. Farha, S. Thind, R. Williams, II
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-1378: Effectiveness and Safety of Isavuconazole Compared with Posaconazole as Primary Antifungal Prophylaxis in High-risk Neutropenic Patients with Hematologic Malignancies and Allogeneic Hematopoietic Cell Transplantation
Presenting author: F. Herrera
Co-authors: D. Torres, N. Mañez, R. Jordán, J. Benso, M. Angel Alderete, Sr., N. Garcia Allende, G. A. Mendez, Sr., M. L. Pereya, L. Tula, A. Manzur, H. I. Peretti, El, C. Salgueira, M. Rodríguez Raimondo, F. Indo, S. Garcia Rojas, P. Callelo, M. Gabriel Castro, V. Fernandéz, A. Risso Patron, C. Niveyro, R. Gago, L. A. Luengo Ackermann, J. Afeltra
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Ceftobiprole data presented at IDWeek 2026

Poster #P-36: Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right-Sided Infective Endocarditis Using Model-Based Approaches
Presenting author: A. Tanudra
Co-authors: C. Lim, K. Rana, C. M. Rubino, D. Lewis, K. B. Larson
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-142: In vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary US Clinical Isolates Collected in 2025 Following FDA Approval
Presenting author: R. E. Mendes
Co-authors: M. Winkler, S. H. Moussa, T. Wiktorowicz, H. Sader, M. Castanheira
Date & time: Thursday, October 22, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Poster #P-381: Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections
Presenting author: K. B. Larson
Co-authors: R. Tummala, N. C. Close, C. M. Rubino, K. Rana, C. Lim, A. Tanudra, S. McLeod, S. Rege, D. Altarac, D. Lewis
Date & time: Saturday, October 24, 2026, 12:15-1:30 pm
Location: Poster Hall B-C

Full PR available here